Tirzepatide Efficacy and Weight Loss Results: A Step-by-Step Look Both medications demonstrate clinically meaningful outcomes, though the magnitude and evidence base differ considerably
Weight loss begins during the escalation phase, but the rate varies significantly between individuals
SCFAs activate free fatty acid receptors FFAR2 and FFAR3 on L-cells, thereby stimulating GLP-1 secretion
Quick look at the key results According to clinical trial investigators, orforglipron: Led to significant weight reduction across all dosing groups Showed greater effects at the highest dose levels Helped lower blood sugar in people with diabetes Supported modest improvements in blood pressure Demonstrated mainly mild to moderate side effects The trial results suggest that the once-daily pill performs competitively with early GLP-1 injection studies
Rieg, T
Stephanie Young Moss, PharmD Medical Reviewer Stephanie Young Moss, PharmD, has worked in pharmacy, community outreach, regulatory compliance, managed care, and health economics and outcomes research